Literature DB >> 7627952

Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.

P Abarzúa1, J E LoSardo, M L Gubler, A Neri.   

Abstract

The p53 tumor suppressor is a transcription factor frequently mutated in human malignancies. Tumor-derived p53 missense mutants are defective in sequence-specific DNA binding and fail to activate p53 target genes. mAb PAb421 was shown previously to restore DNA binding to selected p53 mutants in vitro. Here we show that mAb PAb421 when microinjected into human SW480 colorectal carcinoma cells restores the transcription activation function to the resident mutant p53 (arg to his 273, pro to ser 309). Codon 273 is the second most frequent p53 missense mutant found in human tumors. Our results lend support to the concept of restoring wild-type function to mutant p53 as a strategy for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7627952

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  A novel method for SNP detection using a new duplex-specific nuclease from crab hepatopancreas.

Authors:  Dmitry A Shagin; Denis V Rebrikov; Valery B Kozhemyako; Ilia M Altshuler; Alex S Shcheglov; Pavel A Zhulidov; Ekaterina A Bogdanova; Dmitry B Staroverov; Valery A Rasskazov; Sergey Lukyanov
Journal:  Genome Res       Date:  2002-12       Impact factor: 9.043

2.  Protein delivery using engineered virus-like particles.

Authors:  Stanislaw J Kaczmarczyk; Kalavathy Sitaraman; Howard A Young; Stephen H Hughes; Deb K Chatterjee
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  New Phage Display-Isolated Heptapeptide Recognizing the Regulatory Carboxy-Terminal Domain of Human Tumour Protein p53.

Authors:  Sihem Ben Abid; Mouna Sahnoun; Ines Yacoubi-Hadj Amor; Salma Abdelmoula-Souissi; Hajer Hassairi; Raja Mokdad-Gargouri; Ali Gargouri
Journal:  Protein J       Date:  2017-10       Impact factor: 2.371

4.  The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.

Authors:  C Venot; M Maratrat; C Dureuil; E Conseiller; L Bracco; L Debussche
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

5.  The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent.

Authors:  L Whitesell; P D Sutphin; E J Pulcini; J D Martinez; P H Cook
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

6.  Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies.

Authors:  V Gire; D Wynford-Thomas
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

7.  Down-regulation of beta-catenin by activated p53.

Authors:  E Sadot; B Geiger; M Oren; A Ben-Ze'ev
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

Review 8.  Strategies for manipulating the p53 pathway in the treatment of human cancer.

Authors:  T R Hupp; D P Lane; K L Ball
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

9.  p53 requires an intact C-terminal domain for DNA binding and transactivation.

Authors:  Hyunjung Kim; Kyunghwan Kim; Jongkyu Choi; Kyu Heo; Hwa Jin Baek; Robert G Roeder; Woojin An
Journal:  J Mol Biol       Date:  2011-12-09       Impact factor: 5.469

Review 10.  New p53-based anti-cancer therapeutic strategies.

Authors:  K G Wiman
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.